


# Structure of tumor board and biological reporting: example of ATTRACT

Ludovic Lhermitte,

Necker Hospital, Paris, France

ATTRACT Project – Biological WP leader

- Copenhagen, September 27<sup>th</sup> 2024




# Structure of tumor board and biological reporting: example of ATTRACT

Ludovic Lhermitte,

Necker Hospital, Paris, France

ATTRACT Project – Biological WP leader

- Copenhagen, September 27<sup>th</sup> 2024




# Structure of tumor board and biological reporting: example of ALL-target

Ludovic Lhermitte,

Necker Hospital, Paris, France

ATTRACT Project – Biological WP leader

- Copenhagen, September 27<sup>th</sup> 2024



# Pre-Analytics



Referring  
clinician



R/R T-ALL  
>1 Relapse

# Pre-Analytcs



Referring  
clinician




R/R T-ALL  
>1 Relapse




Diagnostic lab  
(biological board)

# Pre-Analytcs



# Pre-Analytcs



# Analytics



**Fast Shipment**  
**<48h**



# Analytics




Fast Shipment  
<48h




Fresh Sample


# Analytics




# Analytics



# Analytics




# Analytics




- Stage of maturation arrest
- Biomarkers (targets)

# Analytics




- Stage of maturation arrest
- Biomarkers (targets)



- Tofacitinib+Venetoclax
- 5-azacytidine+Venetoclax
- Temsirolimus+Erwinias




# Analytics




# Post-Analytics

Referring  
clinician





Clinical History  
(standardized report)



Diagnostic lab  
(biological board)




Stage of maturation  
Biomarkers (targets)



Targets  
Biomarkers



Drug sensitivity IC50  
Synergy -scores



Clinical board






# Post-Analytics

Referring  
clinician




Clinical History  
(standardized report)


Diagnostic lab  
(biological board)



Stage of maturation  
Biomarkers (targets)



Targets  
Biomarkers



Drug sensitivity IC50  
Synergy -scores

Clinical board



Panel discussion


# Post-Analytics

Referring  
clinician




Clinical History  
(standardized report)


Diagnostic lab  
(biological board)



Stage of maturation  
Biomarkers (targets)



Targets  
Biomarkers



Drug sensitivity IC50  
Synergy -scores

Clinical board



Panel discussion




Final decision:

- ✓ TTO
- ✓ SOC


# Post-Analytics

Referring  
clinician




Clinical History  
(standardized report)


Diagnostic lab  
(biological board)



Stage of maturation  
Biomarkers (targets)



Targets  
Biomarkers



Drug sensitivity IC50  
Synergy -scores

Clinical board




Panel discussion



Final decision:

- ✓ TTO
- ✓ SOC



Follow-up  
response  
NGS at relapse

# Conclusion: lessons & perspectives

## Requirements

Reactivity, fresh samples, tight organization

Close connection and discussion with the referring clinician

## Towards a clinical grade assay

Moving on a more robust assay with quality controls

Formal and uniform reporting

## Integrated approach


Genomic precision medicine

Functional precision medicine

Integrated precision medicine

DT ↔ validating parameter

# Acknowledgements



**Philippe Rousselot**  
**Vahid Asnafi**  
**Lucien Courtois**  
**Mathieu Simonin**  
**Antoine Pinton**  
**Guillaume Andrieu**  
**Mehdi Latiri**  
**Elizabeth Macintyre**

**GRAALL**



**Frank van Leeuwen**



**Eulalia Genesta**

